Walk into a pharmacy in Moscow and ask for Semax. You will walk out with a small bottle of nasal drops and a pipette stopper, because there it is a registered prescription medicine that has been on the shelf since 1994. Doctors prescribe it for stroke, for cerebrovascular disease, for memory and attention problems, and for children from the age of seven.
Try that in Chicago and nobody knows what you are talking about.
That gap is the whole story of this peptide. Semax has a clinical history most nootropics would kill for, forty years of it, and almost none of that history was ever translated, replicated, or run through a Western trial. What reached American biohackers instead was a rumor, a BDNF paper, and a lot of vendor copy written by people who never read either.
We went back through the primary literature for this one, including the Russian package insert, and found that a surprising amount of what circulates about Semax is wrong. Not in a nitpicking way. Wrong in ways that change how you would use it: a dosing figure that is off by a factor of ten, a mechanism paper that says roughly the opposite of what gets attributed to it, and a route question almost nobody is willing to answer straight.
Semax is worth the attention. It is one of the few compounds in this space with a real pharmaceutical life behind it, the BDNF mechanism holds up across independent labs, and the people who run it properly tend to keep running it. Getting it right just takes more care than most pages give it.
The Russian File on Semax
Start where the evidence is thickest, because it is not where American readers usually look.
Semax came out of the Institute of Molecular Genetics at the Russian Academy of Sciences in the 1980s, developed under Igor Ashmarin. Phase I trials ran from 1990 to 1994 and phase II through 1996, after which it entered Russian medical practice. On December 7, 2011 it was added to the country’s List of Vital and Essential Drugs, which is the register a government keeps of medicines it considers necessary to guarantee supply of. That is a meaningful signal. Governments do not put nootropic curiosities on those lists.
The registered indications on the Russian package insert run wider than most people realize: memory and attention disorders, cerebrovascular disease and discirculatory encephalopathy, acute ischemic stroke, recovery after traumatic brain injury and neurosurgery, optic nerve disease, and support for adaptive capacity under extreme mental load. Pediatric use is approved from age seven. Russian clinical practice has also used it in peptic ulcer and Parkinson’s disease.
The stroke file is the deepest part. A Russian meta-analysis pooling eight studies across 654 patients found intranasal Semax given in the first 10 to 14 days after ischemic stroke associated with better recovery, which is the evidence base that keeps it in hospital protocols there.
None of this is FDA approval, and it should not be sold as such. Russian registration standards from the 1990s were not FDA standards, most of the supporting work was published in Russian-language journals with limited Western peer review, and no Phase III program ever tested Semax in the United States. What it does mean is that Semax has been given to a very large number of people, under medical supervision, for a very long time, and the safety record that emerged from that is part of why the compound has the reputation it does.
Where we send readers
Paramount Semax, in the 30mg vial most shops don’t carry
Base Semax, the molecule the Russian literature was built on. Synthesized in-house in Southern California, 99%+ by HPLC, with the Janoshik COA posted on the page before you pay. The reason we point here rather than anywhere else is the vial size. Most shops stop at 10mg and charge accordingly.
Typical 10mg vial
$4 to $5 per mg
What most shops charge for the small size. About sixteen mornings at 600 mcg, then you are reordering.
About half the cost per mg
Paramount 30mg
$68.00
About $2.27 per mg. Fifty mornings at 600 mcg, three full courses in one vial. This is the size that changes the economics.
Code BRAINFLOW takes 10% off. Sold for research use only. Pricing moves.
Seven Amino Acids, and the One Detail Every Site Gets Wrong
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro. Seven residues, which is where the name comes from.
Nearly every page you will read describes Semax as “ACTH(4-10) with a Pro-Gly-Pro tail added.” Count the letters and that cannot be right. ACTH(4-10) is seven residues on its own, MEHFRWG. Bolt three more onto it and you have ten, not seven.
The real construction is the ACTH(4-7) fragment, MEHF, with Pro-Gly-Pro attached. Four plus three. The literature calls it an ACTH(4-10) analog because that is the fragment it was functionally derived from, and the original Dolotov paper title uses that phrasing, so the shorthand is defensible. Saying ACTH(4-10) plus PGP is not. It is a small thing, and it is also a reliable tell for whether a page was assembled from other pages or from the source material.
The reason for the tail is the interesting part. The bare ACTH fragment is useful in the brain but useless as a drug, because blood enzymes strip it apart almost immediately, working in from the N-terminus and taking the methionine first. Adding Pro-Gly-Pro gave the molecule broad resistance to peptidases and bought enough time for it to do something. That tail is the entire invention, and it turns out to have modest activity of its own.
Full ACTH tells your adrenal glands to release cortisol. The 4-7 fragment keeps the neural activity and drops the hormonal signal, which is why Semax does not behave like a stress hormone despite its ancestry.
What Semax Does Once It Reaches the Brain
BDNF is the headline, and it has held up well.
Brain-derived neurotrophic factor is the growth factor most closely tied to neuroplasticity, learning, and keeping existing neurons healthy. If a compound raises it reliably, that compound is worth paying attention to.
Dolotov and colleagues, writing in Brain Research in 2006, gave rats a single intranasal dose at 50 micrograms per kilogram and measured what happened in the hippocampus. BDNF protein rose 1.4-fold. Phosphorylation of TrkB, the receptor BDNF signals through, rose 1.6-fold. The mRNA changes were larger: BDNF exon III transcripts up threefold, TrkB transcripts up twofold. Performance on a learning task moved alongside the chemistry. A companion paper from the same group found specific binding in the basal forebrain.
One dose. That is the part worth sitting with, because it explains why people report something on the first or second morning rather than after three weeks of accumulation.
The neurotrophin effect extends past BDNF. Dmitrieva and colleagues, in Cellular and Molecular Neurobiology in 2010, looked at rat brains after induced ischemia and found Semax switching on BDNF, TrkC and TrkA within three hours, then NT-3 and NGF by twenty-four hours, with NGF still elevated at seventy-two. They also tested the Pro-Gly-Pro tail by itself, which produced changes of its own, though the authors were careful to note that Semax acted selectively on ischemic cortex while the tail’s influence was mostly nonspecific. Worth knowing next time someone tries to sell you PGP as a budget substitute.
The monoamine story is more specific than most pages report. Eremin and colleagues, in Neurochemical Research in 2005, found striatal serotonin metabolites climbing steadily for hours after a single dose, reaching 180% of baseline. Dopamine is where the nuance sits. Semax on its own did not move dopamine or its metabolites at all. It only showed a dopaminergic effect when given alongside amphetamine, where it sharply amplified the release. So Semax modulates that system rather than driving it, which fits the reports of drive without a stimulant signature better than a simple dopamine-boost story would. Like its sister compound Selank, it also slows the enzymes that break down enkephalins.
A correction on the inflammation claim
You will see it written that Semax lowers IL-1 beta, TNF alpha and IL-6 in stroke models, usually citing a 2014 paper by Medvedeva. We pulled that paper. It does not say that.
The study, published in BMC Genomics, is a genome-wide microarray looking at gene transcription in rat brain after focal ischemia. It measured messenger RNA rather than protein, and it never reports those three cytokines individually. What it found was that immune-response genes made up more than half of everything Semax altered at twenty-four hours, with immunoglobulin and cytokine genes moving up, alongside changes in calcium regulation and vascular development.
That is a more interesting result than the version people repeat. Semax appears to be reorganizing the immune and vascular response to injury rather than simply damping inflammation down, which fits a recovery drug better than a blunt anti-inflammatory would. It is just not the claim that gets attached to it.
The Route Question Nobody Answers Straight
This is where we part company with most of the internet, and it matters more for your results than anything else in this article.
Every human study of Semax used the nose. The Russian pharmaceutical product is nasal drops, sold at 0.1% and 0.5% strengths in a bottle with a pipette. The stroke meta-analysis used intranasal dosing. The fMRI work in healthy volunteers used intranasal instillation. Dolotov’s BDNF result came from intranasal dosing in rats. There is no registered injectable Semax anywhere in the world.
Searching the indexed literature for subcutaneous Semax efficacy data turns up nothing. Not a weak study, not a small study. Nothing.
Meanwhile, a large share of people who buy a lyophilized research vial reconstitute it and inject it, on the reasoning that subcutaneous delivery gives close to full absorption while nasal mucosa gives perhaps sixty or seventy percent, and that the difference is worth the needle. You will find that argument all over the forums, stated with total confidence.
It is a guess. A reasonable-sounding guess, drawn from how other peptides behave, but nobody has measured it for this molecule. And there is a specific reason to be careful with the assumption here: intranasal delivery gives small peptides a partial shortcut into the central nervous system along the olfactory and trigeminal pathways, which is exactly the property you would want from a compound whose target is the hippocampus. Higher systemic absorption is not automatically better when the destination is your brain.
Our read, stated plainly. If you want to replicate what the research established, use the nose, because that is the only route with evidence attached to it. Reconstituted Semax solution can be dosed nasally without any special equipment. Plenty of people inject it and report results, and we are not going to pretend those reports do not exist, but anyone telling you injection is the proven route has it backwards. The proven route is the one the Russians have been using for thirty years.
Both camps agree on one thing. Oral Semax is a waste of money. Peptide bonds do not survive digestion, and no study has ever used that route. Capsules with the Dolotov paper cited on the label are selling you the paper, not the effect.
Semax and Focus, and What the Human Data Shows
Most readers are not here for stroke recovery. They are here because they want to think clearly for six hours without a stimulant taking the wheel, and they heard Semax does that.
The good news is that healthy-volunteer research exists. The odd thing is that almost nobody cites it, which tells you how few people writing about this peptide have gone looking.
Lebedeva and colleagues, in the Bulletin of Experimental Biology and Medicine in 2018, put twenty-four healthy adults through resting-state fMRI before dosing, then again at five and twenty minutes after intranasal Semax. Fourteen got the peptide and ten got placebo. The Semax group showed a larger rostral subcomponent of the default mode network, centered on medial frontal cortex. That region is part of the machinery your brain uses to switch between internal and external attention.
The same group followed up in 2020 with fifty-two participants, comparing Semax, Selank and placebo on the same protocol. This time the signal showed up in functional connectivity between the right amygdala and right temporal regions, including fusiform and parahippocampal cortex.
Two things about those studies. First, they are real measurements in real people, on the route the Russians use, showing brain-state changes within twenty minutes. That is a stronger footing than most nootropics manage. Second, they are small, unreplicated outside one research group, and they measure brain activity rather than whether you got more work done. Nobody has run a proper cognitive performance trial in healthy adults.
Going further back, a 1996 paper by Kaplan and Ashmarin in Neuroscience Research Communications reported nootropic-like activity in humans with attention and EEG measures. It is the earliest human cognition work on the compound, and it is also a thirty-year-old paper in a journal that no longer exists, so treat it as history rather than proof.
Worth flagging what is not there. You will find claims about Semax cutting error rates by eighteen percent in military operators during long vigilance shifts. We went looking for that study. It does not appear to exist. The figure shows up on vendor pages with no author, no year, and no journal, which is usually what a fabricated statistic looks like. Semax does not need it.
The pattern is consistent enough to be useful. Semax is a recovery and plasticity compound that happens to sharpen attention, rather than a stimulant that happens to be neuroprotective. People who expect the second thing tend to be disappointed. People who expect the first tend to stay.
How Much Semax People Use
A number is circulating that needs killing before anything else.
Multiple sites state that Russian stroke protocols use 1,200 to 1,800 micrograms per day. The real figure from the clinical literature is 12 to 18 milligrams per day of the 1% solution, given intranasally over the first ten to fourteen days. The package insert puts moderate stroke at 6,000 to 12,000 micrograms daily and severe stroke at 12,000 to 20,000.
That is ten times what gets quoted. The error almost certainly started as a milligram-to-microgram slip that then got copied from page to page without anyone checking. It matters because a reader who sees “hospitals use 1,800 mcg” might reasonably conclude that 900 is a conservative dose, when the hospital number is a different order of magnitude and a different clinical situation entirely.
For non-stroke use, the registered Russian ranges are wide. Adaptive-capacity support runs 400 to 900 micrograms daily. Optic nerve indications run 600 to 900. Pediatric use from age seven runs 200 to 400. The memory and attention indication is the broad one, spanning 200 to 2,000 micrograms per dose and 800 to 8,000 per day depending on severity.
Set against that, the community range of 200 to 1,000 micrograms a day sits at the very bottom of the registered Russian scale, closest to the adaptive-capacity indication. Which is arguably where a healthy person should sit, given that every registered indication above it describes someone with a diagnosed problem.
Most logs cluster in the 300 to 600 microgram band, taken in the morning, in courses of ten to fourteen days followed by a similar break. The cycling convention comes straight from the Russian outpatient charts and seems to hold up in practice, since continuous daily use is the most common thing people blame when the effect fades.
Turning powder into micrograms
Research Semax, Paramount’s 30mg vial included, arrives as lyophilized powder. Bacteriostatic water goes in, the cake dissolves with gentle rolling rather than shaking, and the vial lives in the fridge afterward. The arithmetic below uses 2 mL of water for a 10mg vial and 3 mL for the 30mg, which lands each one at a concentration where the syringe marks are easy to read.
The practical consequence of that table is worth spelling out. Put only 2 mL into the 30mg vial and you are at 15 mg/mL, where 300 micrograms is two units and a small slip is a large percentage error. Three mL brings it to 10 mg/mL, where 300 is three units, 600 is six and 900 is nine, all comfortable, readable marks on a U-100 syringe. Match the water to the vial and the arithmetic stays clean.
Label the cap with the vial size and the water volume the moment it is mixed. Nine days later nobody remembers, and a 10mg vial at 2 mL is half the concentration of a 30mg vial at 3 mL.
What a Fourteen-Day Semax Course Feels Like
Composite drawn from years of forum logs across LongeCity, the older nootropics communities, and reader mail. Placebo and vendor quality are both baked into any account like this, so read it as a map of expectations rather than a prediction.
The first session is where Semax surprises people. A meaningful share of users report something within twenty to forty minutes, usually described as sentences arriving more easily and less friction getting started on work. Given that Dolotov measured BDNF changes from a single dose, a same-day effect is not implausible. Others feel nothing until day two or three, which is equally common and not a sign of a bad vial.
Through days two to four the reports converge on two things: verbal fluency and the ability to stay on one task without drifting. Writers and people who talk for a living notice it most. If a headache shows up in this window, it usually belongs to someone who started at 900 micrograms instead of working up.
Week two is the part that tells you something. The common report is not a bigger effect but a steadier baseline, described more often as feeling like a good version of your normal self than as feeling altered. This is also where people who dose every single day without a break start reporting the effect going flat.
After the course, most people take ten to fourteen days off and find the next run works about as well as the first. The pulsed pattern comes from the Russian charts and the community adopted it because continuous use appears to blunt the response.
Two recurring notes from the logs worth passing on. Semax stacked with Selank is the pairing people return to most often, focus alongside calm. And Semax combined with modafinil produces an oddly high number of reports of getting sleepy, which nobody has a good explanation for.
A minority feel nothing at all and move on. That is true of every nootropic ever sold, and with peptides specifically, a dead vial from a bad vendor is the first thing worth ruling out, which is the whole argument for buying from a source that posts the COA.
Base Semax, N-Acetyl Semax, and NASA
Three versions of this compound are sold, and the marketing around the modified ones has gotten ahead of the evidence.
The chemistry behind the modified versions is not nonsense. Recall that blood enzymes attack Semax from the N-terminus, taking the methionine first. Capping that end with an acetyl group blocks the opening move directly, and amidating the other end closes the remaining exposure. Published stability work gives N-Acetyl Semax Amidate roughly thirty extra minutes of resistance to leucine aminopeptidase compared to the base molecule.
Thirty minutes of extra stability is not the same as two to three times the potency, which is the number vendors attach to NASA. That multiplier has no source. No head-to-head study of NASA against base Semax exists on any efficacy endpoint, and even sites that sell it and like it stop short of the claim.
Our position is straightforward. Base Semax is the molecule with forty years of clinical use, a meta-analysis, two fMRI studies and a government drug registration behind it. The modified versions may well turn out to be better and nobody has shown it yet. Buying the version the research studied is the reasonable default, and it is usually cheaper.
Semax Next to Selank and Next to Stimulants
Semax and Selank came out of the same institute, from the same research program, and people constantly ask which one to buy. They are not competing for the same slot.
Semax leans toward focus, drive and neurotrophic signaling. Selank leans toward calm, taking the edge off anxiety without sedation. Running both is common, and the usual complaint from people who dislike the combination is that they took them together without deciding what each one was for.
Against prescription stimulants, the comparison is less useful than it looks. Amphetamine and methylphenidate work through catecholamine reuptake, have enormous approved trial programs behind them, and are scheduled drugs prescribed for a diagnosed condition. Semax works through neurotrophins and monoamine modulation, has a foreign clinical file and animal data, and is sold as a research compound. Reports that Semax noticeably changes how a prescribed stimulant feels are common enough that anyone on one should raise it with their prescriber rather than experimenting quietly.
What Semax offers is the thing stimulants do not: a clean ceiling. Nobody describes it as euphoric, nobody reports a crash, and the most common phrase in the logs is some version of feeling like themselves on a good day.
Semax Side Effects
For a compound with this much clinical exposure, the side effect profile is unusually quiet.
Russian hospital papers noted nasal irritation and discoloration in some patients, which follows from decades of intranasal dosing and is the most commonly documented complaint. Community reports add first-week headache, irritability when the amount creeps upward, and trouble sleeping in anyone dosing late in the day. Semax has a long enough tail that an afternoon dose can still be working at bedtime.
Almost all of these track with dose. The headache and irritability reports cluster around people who opened at the top of the range rather than building up, which is a good argument for starting low regardless of how eager you are.
Situations where it makes sense to stay away: pregnancy and breastfeeding, since no data exists; any diagnosed neurological or psychiatric condition being managed without a clinician in the loop; and tested athletics, for reasons covered below. Anyone who reacts badly to stimulants generally reports Semax more comfortably than caffeine, though starting at the bottom of the range still applies.
The real limitation is that long-term Western safety data does not exist. Thirty years of Russian prescribing is reassuring and it is not the same thing as a controlled follow-up study in healthy adults using it for focus.
Where Semax Stands Legally After July 2026
Older versions of this guide said an FDA advisory committee was due to look at Semax. That meeting has now happened, and the outcome went Semax’s way.
On July 24, 2026, the Pharmacy Compounding Advisory Committee voted 8 to 5 with one abstention to recommend both Semax free base and Semax acetate for inclusion on the 503A Bulks List, the register of substances that compounding pharmacies may legally prepare. The indications reviewed were cerebral ischemia, migraine and trigeminal neuralgia. The same two-day meeting recommended BPC-157, TB-500, KPV, MOTS-c and Epitalon. Emideltide was the only one of the seven to be turned down. In a detail that surprised most observers, the committee voted in favor despite FDA scientific staff recommending against listing any of them.
What a favorable vote does and does not do is where most coverage gets sloppy. The committee advises. The FDA decides, and it is not bound by the recommendation. Formal notice-and-comment rulemaking is the step that would let a pharmacy compound Semax, and that process has not started. Estimates for how long it runs once it does range from six months to two years.
Nothing changed legally the day after that vote. Semax is still not an FDA-approved drug in the United States, still has no USP monograph, and research-grade material is still sold for laboratory use. What did change is the direction of travel, and a federal advisory panel looking at the Russian evidence base and voting yes over its own agency’s objection is not nothing.
For tested athletes the answer is simpler and less encouraging. Semax is not named on the 2026 WADA Prohibited List, but the S0 category covers any substance with no approval from a government health authority, which is precisely where Semax sits. That makes it prohibited at all times regardless of its absence from the named list. Selank is in the same position. Anyone subject to testing should treat both as off limits rather than reading the omission as a loophole.
Buying Semax Without Getting Burned
Peptide quality is the variable that decides whether any of the above applies to the vial in your fridge.
Insist on a named third-party lab, a Certificate of Analysis you can read before paying rather than after, milligram content printed on the vial, and a vendor with enough history that they will still exist when you want a second one. What should end the conversation is no COA, a certificate that does not match your batch number, oral Semax sold with claims borrowed from injection or nasal studies, NASA marketed as though it were the compound Russian hospitals use, and prices that make no sense in either direction.
On price specifically, the market has a structural problem. Most vendors sell Semax only in 10mg vials, which puts the cost somewhere between four and five dollars per milligram once you account for typical pricing. At 600 micrograms a day, a 10mg vial is a little over two weeks, so anyone running repeat courses is buying vials constantly at the worst possible rate.
Paramount Peptides is where we point readers, for two reasons. They synthesize base Semax in-house in Southern California, verify every lot by HPLC and mass spec, and post the Janoshik COA on the product page before you pay, with documented lots going back to 2025. And they sell it in a 30mg vial at $68.00, which works out to about $2.27 per milligram against the four to five dollars most 10mg vials cost. At 600 micrograms a day that is fifty mornings, three full courses with room to spare, from one purchase instead of three.
The vial that fixes the math
Three courses in one vial, or one course in three
A 10mg vial is about sixteen mornings at 600 mcg. Paramount’s 30mg is about fifty. Base Semax, HPLC and mass spec on every lot, Janoshik COA on the page. The only thing that changes is whether you are reordering every two weeks at four dollars a milligram.
One course
10mg · $4 to $5/mg
The typical small vial. Fine as a first test, expensive as a habit.
Three courses
Paramount
30mg · $68.00
About $2.27/mg before the code. Bigger than the 10mg most shops stop at.
Code BRAINFLOW takes 10% off. Sold for research use only. Pricing moves.
Semax Questions We Get Asked
Is Semax a real medicine or just a research chemical?
Both, depending on the country. Russia has prescribed it since the mid-1990s and added it to the List of Vital and Essential Drugs in December 2011, where it is used for stroke, cerebrovascular disease, memory and attention disorders, and optic nerve conditions. In the United States it has no approval and no monograph, and it is sold for laboratory use.
Should Semax be used nasally or injected?
Every human study and the registered Russian product use the nasal route, and no published efficacy data exists for subcutaneous Semax in any species. Many people with a research vial inject it anyway, reasoning that absorption is higher, but that reasoning has never been tested for this molecule. Nasal delivery also offers small peptides a partial direct path to the brain, which is where Semax is meant to act.
How much Semax do people take?
Community practice runs roughly 200 to 1,000 micrograms daily, with most reports clustering between 300 and 600, taken in the morning across courses of ten to fourteen days. That sits at the bottom of the registered Russian range, whose lowest indication is 400 to 900 micrograms a day for adaptive-capacity support.
Is it true that Russian hospitals use 1,200 to 1,800 mcg for stroke?
No, and this is the most repeated error about Semax online. The clinical figure is 12 to 18 milligrams per day of 1% solution over the first ten to fourteen days, with the package insert listing 6,000 to 12,000 micrograms for moderate stroke and 12,000 to 20,000 for severe. The commonly quoted number is off by a factor of ten.
How fast does Semax work?
Faster than most nootropics. Dolotov measured BDNF and TrkB changes in rats from a single dose, and the fMRI studies in healthy volunteers picked up brain-state changes within twenty minutes of dosing. Many users report something on the first morning, though feeling nothing until day two or three is equally common.
Is NASA stronger than regular Semax?
No study has compared them. N-Acetyl Semax Amidate is capped at both ends, which does improve stability in laboratory measurements by around thirty minutes against one degrading enzyme. The two-to-three-times-stronger figure that circulates has no published source. Base Semax is the version the entire clinical literature is built on.
Can Semax be taken orally?
No. Peptide bonds are broken down in the digestive tract, and not a single study of Semax has used the oral route. Capsules citing the nasal research on their label are borrowing evidence that does not transfer.
Does Semax show up on a drug test?
Standard employment screening does not look for peptides. For WADA-tested athletes the situation is different. Semax is not named on the 2026 Prohibited List, but the S0 category captures substances with no health-authority approval, which includes Semax and Selank both. Treat it as prohibited rather than unlisted.
Semax or Selank?
Semax for focus, drive and neurotrophic support. Selank for calm and anxiety without sedation. They came from the same Russian research program and are frequently run together, since they address different problems rather than competing.
Where can I buy Semax?
We point readers to Paramount Peptides, who make base Semax in-house in the USA with HPLC and mass spec verification and a Janoshik COA posted before purchase, in a 30mg vial at $68.00. That size is bigger than the 10mg most shops stop at and brings the cost down to about $2.27 per milligram, roughly half the usual rate. Code BRAINFLOW takes 10% off.
Where That Leaves Semax
Semax has something almost nothing else in this category can claim. A government put it on the list of medicines it considers essential. Doctors have prescribed it to children and stroke patients for three decades. The BDNF mechanism replicates. Two fMRI studies show measurable brain changes in healthy people within twenty minutes. A federal advisory committee in the United States looked at all of it in July and voted yes.
It also has a Western evidence gap that no amount of enthusiasm closes. The focus research is two small imaging studies from one group. The safety record is Russian clinical experience rather than modern controlled follow-up. And a lot of what circulates online about dosing, mechanism and routes turns out, on checking, to be copied rather than sourced.
None of that makes it a bad bet. It makes it a compound that rewards getting the details right. Use base Semax rather than a modified version with no file behind it. Use the route the research used. Sit at the bottom of the Russian range rather than chasing a stroke dose you misread by a factor of ten. Run it in courses with breaks, the way the charts it came from specify. Do those four things and you are running Semax closer to correctly than most people who have ever bought it.
And buy something you can verify. Paramount Peptides carries base Semax in a 30mg vial, made in-house in the USA with HPLC and mass spec on every lot and the Janoshik COA on the page, and code BRAINFLOW takes 10% off. A peptide this cheap to fake is not worth guessing about.
Semax is sold in the United States as a research peptide for laboratory use only and is not FDA-approved. Amounts described here are drawn from published research and the Russian package insert as context, not as instructions. This article is educational and is not medical advice. Consult a qualified clinician before beginning any protocol.
This article contains affiliate links. BrainFlow may earn a commission on qualifying purchases at no additional cost to the reader. We only recommend sources we trust.
Last updated September 2026.
3 Comments